Form 4: Kymera CEO Exercises Options, Boosts Share Count

Kymera Therapeutics CEO Nello Mainolfi exercised stock options to acquire 3,118 shares of common stock, increasing his direct beneficial ownership.

Summary

• Nello Mainolfi, the Chief Executive Officer and a Director of Kymera Therapeutics, Inc. (KYMR), exercised stock options.
• He acquired 3,118 shares of Kymera Therapeutics common stock at an exercise price of $32.07 per share.
• The transaction took place on January 5, 2026.
• Following this exercise, Mainolfi directly beneficially owns 666,195 shares of common stock.
• The exercised stock options were part of a grant that vests in thirty-six equal monthly installments, commencing March 1, 2023, contingent on Mainolfi's continued employment.
• After the transaction, Mainolfi holds 446,882 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The exercise of stock options by a CEO, leading to an increase in direct share ownership, is generally viewed as a positive signal of management's confidence in the company's future prospects.

Positives

• CEO Nello Mainolfi increased his direct beneficial ownership of Kymera Therapeutics common stock by 3,118 shares.
• The exercise of stock options demonstrates continued engagement and potential confidence in the company's future performance by a key executive.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as the exercise of stock options, are routine disclosures that provide transparency into executive compensation and ownership changes. While not directly indicative of broader industry trends, they offer insights into individual executive's equity positions.

Stakeholder Impact

• Shareholders may interpret the CEO's increased direct ownership as a positive signal of management's commitment and belief in the company's long-term value.

Next Steps

• Continued vesting of remaining stock options, subject to the reporting person's continued employment through each vesting date.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Nello Mainolfi, CEO, Director, Stock Options, Insider Transaction, Form 4, Beneficial Ownership, Equity, Common Stock